Evidence map›Paper›PMID 40509212›Full record

ArticleMolecules (Basel, Switzerland)2025

In Silico Identification and Characterization of Spiro[1,2,4]triazolo[1,5-

Lyudmyla Antypenko, Kostiantyn Shabelnyk, Oleksii Antypenko, Mieko Arisawa, Oleksandr Kamyshnyi, Valentyn Oksenych, Serhii Kovalenko

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. The Constituents ofScientifica · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lyudmyla AntypenkoIndependent Researcher, 11 Lamana Str., 69063 Zaporizhzhia, Ukraine.ORCID 0000-0003-0057-1551
Kostiantyn ShabelnykDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, 26 Maria Prymachenko Blvd., 69035 Zaporizhzhia, Ukraine.ORCID 0000-0003-2008-8380
Oleksii AntypenkoDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, 26 Maria Prymachenko Blvd., 69035 Zaporizhzhia, Ukraine.ORCID 0000-0002-8048-445X
Mieko ArisawaGraduate School of Bioresources and Bioenvironmental Sciences, Kyushu University, 744 W5-674, Motooka Nishi-ku, Fukuoka 819-0395, Japan.
Oleksandr KamyshnyiDepartment of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil State Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0003-3141-4436
Valentyn OksenychDepartment of Clinical Science, University of Bergen, Langes Gate 1-3, 5020 Bergen, Norway.ORCID 0000-0002-5088-3791
Serhii KovalenkoInstitute of Chemistry and Geology, Oles Honchar Dnipro National University, 72 Nauky Ave., 49010 Dnipro, Ukraine.ORCID 0000-0001-8017-9108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new class of spiro[1,2,4]triazolo[1,5-

Indexed as

Diacylglycerol KinaseQuinazolinesAnimalsBinding SitesComputer SimulationHumansMolecular Docking SimulationMolecular StructureProtein BindingStructure-Activity RelationshipDiacylglycerol KinaseQuinazolinescomputational drug designdiacylglycerol kinasemolecular dockingspirotriazoloquinazolinesstructure–activity relationships

Identifiers

PMID40509212
PMCPMC12156019

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.